|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 433 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Chronic Obstructive Pulmonary Disease (COPD) Overview
- Therapeutics Development
- An Overview of Pipeline Products for Chronic Obstructive Pulmonary Disease (COPD)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics under Development by Companies
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Products under Development by Companies
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Development
- Johnson & Johnson
- Boehringer Ingelheim GmbH
- Kyowa Hakko Kirin Co., Ltd.
- Osiris Therapeutics, Inc.
- Amgen Inc.
- AstraZeneca PLC
- GlaxoSmithKline plc
- MedImmune LLC
- Daiichi Sankyo Company, Ltd
- Merck & Co., Inc.
- Pearl Therapeutics, Inc.
- Nycomed International Management GmbH
- Rib-X Pharmaceuticals, Inc.
- Novartis AG
- REVOTAR Biopharmaceuticals AG
- Aquinox Pharmaceuticals Inc.
- Aridis Pharmaceuticals LLC
- ProtAffin Biotechnologie AG
- Funxional Therapeutics Ltd
- Promedior, Inc.
- Pulmatrix, Inc.
- MSM Protein Technologies, Inc.
- Reata Pharmaceuticals, Inc.
- AIM Therapeutics Inc.
- BioMarck Pharmaceuticals, Ltd.
- Vantia Therapeutics
- Inverseon, Inc.
- Polyphor Ltd.
- NanoBio Corporation
- Sparsha Pharma International Pvt. Ltd.
- iNova Pharmaceuticals (Australia) Pty Limited
- Adamis Pharmaceuticals Corporation
- SuppreMol GmbH
- Stelic Institute & Co.
- Pierre Fabre Medicament
- Aphoenix, Inc.
- MicroDose Therapeutx, Inc.
- Elevation Pharmaceuticals, Inc.
- Beech Tree Labs, Inc.
- N30 Pharmaceuticals
- Errant Gene Therapeutics, LLC
- Stempeutics Research Private Limited
- Clarassance, Inc.
- Chronic Obstructive Pulmonary Disease (COPD) – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Daliresp - Drug Profile
- AMG 108 - Drug Profile
- GSK573719 - Drug Profile
- GSK961081 - Drug Profile
- MK-4305 - Drug Profile
- PF-3715455 - Drug Profile
- Cipro Inhale - Drug Profile
- PH-797804 - Drug Profile
- KHK4563 - Drug Profile
- AZD2423 - Drug Profile
- OPC-6535 - Drug Profile
- AZD1981 - Drug Profile
- Prochymal - Drug Profile
- NVA-237 - Drug Profile
- NVA-237 - Drug Profile
- Tudorza Pressair - Drug Profile
- QVA-149 - Drug Profile
- AIM-102 - Drug Profile
- AZD1419 - Drug Profile
- AZD5069 - Drug Profile
- CHF-5407 - Drug Profile
- GSK-1160724 - Drug Profile
- Aerosol Cyclosporine - Drug Profile
- PT-005 - Drug Profile
- Etanercept + Levofloxacin - Drug Profile
- Erdosteine - Drug Profile
- PT-001 - Drug Profile
- PT-002 + PT-009 - Drug Profile
- PT-010 - Drug Profile
- PT-003 - Drug Profile
- GRC 4039 - Drug Profile
- EL-246 - Drug Profile
- GSK573719 + GW642444 - Drug Profile
- Theophylline - Drug Profile
- R65 - Drug Profile
- Neu-164 - Drug Profile
- Fluticasone + Formoterol - Drug Profile
- SM101 - Drug Profile
- Apocynin - Drug Profile
- Dulera - Drug Profile
- PA-401 - Drug Profile
- AZD5423 - Drug Profile
- Formoterol Fumarate + Fluticasone propionate - Drug Profile
- Panaecin - Drug Profile
- Lovastatin - Drug Profile
- Glycopyrrolate - Drug Profile
- Advair - Drug Profile
- Tadalafil - Drug Profile
- Fluticasone + Salmeterol - Drug Profile
- CR-2039 - Drug Profile
- CK-2019165 - Drug Profile
- RBx 10017609 - Drug Profile
- RV-568 - Drug Profile
- EryDex - Drug Profile
- Drug for Respiratory Disease - Drug Profile
- Budesonide + Formoterol - Drug Profile
- fluticasone + salmeterol - Drug Profile
- AQX-1125 - Drug Profile
- Drug For Chronic Bronchitis - Drug Profile
- Antofloxacin Hydrochloride - Drug Profile
- budesonide - Drug Profile
- Recombinant Alpha1-Proteinase Inhibitor - Drug Profile
- LAS100977 + ICS - Drug Profile
- AZD2115 - Drug Profile
- SUN-461 - Drug Profile
- Tulobuterol Patch - Drug Profile
- Budesonide + Formoterol - Drug Profile
- Fluticasone + Salmeterol - Drug Profile
- MEDI2338 - Drug Profile
- BCT-197 - Drug Profile
- Inhaled rhPTX-2 - Drug Profile
- PUR118 - Drug Profile
- Stempeucel- COPD - Drug Profile
- V0162 - Drug Profile
- Acetylsalicylic Acid - Drug Profile
- Drug For COPD - Drug Profile
- Prednisolone - Drug Profile
- N9 Series Oral - Drug Profile
- Myosin Inhibitor - Drug Profile
- RESP-1000 - Drug Profile
- RESP-2000 - Drug Profile
- Doxycycline - Drug Profile
- Tiotropium - Drug Profile
- PD3766 - Drug Profile
- formoterol - Drug Profile
- Doxycycline - Drug Profile
- N6022 Inhaled - Drug Profile
- Inhaled PPAR gamma Agonist Program - Drug Profile
- ALVESCO HFA + Brovana - Drug Profile
- YHD001 - Drug Profile
- LAS100977 - Drug Profile
- EP-101 - Drug Profile
- Drug For COPD - Drug Profile
- Selective PI3K-Delta/Gamma Dual Inhibitors - Drug Profile
- AMA0247 - Drug Profile
- Glycopyrrolate + Beclomethasone + Formoterol - Drug Profile
- COPD VAST Program - Drug Profile
- OCID 2987 - Drug Profile
- MSM-042 - Drug Profile
- APC-1000 - Drug Profile
- PNQ-103 - Drug Profile
- CT-112 - Drug Profile
- SB021 - Drug Profile
- FP-003 - Drug Profile
- LAS190792 - Drug Profile
- CG459 - Drug Profile
- LABA + LAMA - Drug Profile
- ALX-08 - Drug Profile
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Drug Profile Updates
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Discontinued Products
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Dormant Products
- Chronic Obstructive Pulmonary Disease (COPD) – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2012
- Products under Development for Chronic Obstructive Pulmonary Disease (COPD) – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Development by Companies, H2 2012 (Contd..3)
- Number of Products under Development by Companies, H2 2012 (Contd..4)
- Number of Products under Development by Companies, H2 2012 (Contd..5)
- Number of Products under Development by Companies, H2 2012 (Contd..6)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Development by Companies, H2 2012 (Contd..3)
- Products under Development by Companies, H2 2012 (Contd..4)
- Products under Development by Companies, H2 2012 (Contd..5)
- Products under Development by Companies, H2 2012 (Contd..6)
- Products under Development by Companies, H2 2012 (Contd..7)
- Products under Development by Companies, H2 2012 (Contd..8)
- Products under Investigation by Universities/Institutes, H2 2012
- Johnson & Johnson, H2 2012
- Boehringer Ingelheim GmbH, H2 2012
- Kyowa Hakko Kirin Co., Ltd., H2 2012
- Osiris Therapeutics, Inc., H2 2012
- Amgen Inc., H2 2012
- AstraZeneca PLC, H2 2012
- GlaxoSmithKline plc, H2 2012
- MedImmune LLC, H2 2012
- Daiichi Sankyo Company, Ltd, H2 2012
- Merck & Co., Inc., H2 2012
- Pearl Therapeutics, Inc., H2 2012
- Nycomed International Management GmbH, H2 2012
- Rib-X Pharmaceuticals, Inc., H2 2012
- Novartis AG, H2 2012
- Axcan Pharma Inc., H2 2012
- Chiesi Farmaceutici SpA, H2 2012
- Glenmark Pharmaceuticals Ltd., H2 2012
- Kissei Pharmaceutical Co., Ltd., H2 2012
- Meda AB, H2 2012
- Mylan Inc., H2 2012
- Orion Corporation, H2 2012
- Pfizer Inc., H2 2012
- Sun Pharmaceutical Industries Limited, H2 2012
- Bayer AG, H2 2012
- OPKO Health, Inc., H2 2012
- PARI Pharma GmbH, H2 2012
- Alchemia Limited, H2 2012
- Almirall, S.A., H2 2012
- Orchid Chemicals & Pharmaceuticals Ltd, H2 2012
- Pacgen Biopharmaceuticals Corporation, H2 2012
- Pharmaxis Ltd., H2 2012
- Cytokinetics, Inc, H2 2012
- Yuhan Corporation, H2 2012
- SciClone Pharmaceuticals, Inc., H2 2012
- Cytomedix, Inc., H2 2012
- Dynavax Technologies Corporation, H2 2012
- Phytopharm Plc, H2 2012
- Asterand plc., H2 2012
- Torrent Pharmaceuticals Limited, H2 2012
- Biotie Therapies Corp., H2 2012
- Neurim Pharmaceuticals (1991) Ltd., H2 2012
- Synairgen plc, H2 2012
- Galapagos NV, H2 2012
- Orexo AB, H2 2012
- Sucampo Pharmaceuticals, Inc., H2 2012
- Proteo, Inc., H2 2012
- Verona Pharma Plc, H2 2012
- Advinus Therapeutics Pvt. Ltd., H2 2012
- Alba Therapeutics Corporation, H2 2012
- Palau Pharma S.A, H2 2012
- LigoCyte Pharmaceuticals, Inc., H2 2012
- Respiratorius AB, H2 2012
- Ache Laboratorios Farmaceuticos S/A, H2 2012
- REVOTAR Biopharmaceuticals AG, H2 2012
- Aquinox Pharmaceuticals Inc., H2 2012
- Aridis Pharmaceuticals LLC, H2 2012
- ProtAffin Biotechnologie AG, H2 2012
- Funxional Therapeutics Ltd, H2 2012
- Promedior, Inc., H2 2012
- Pulmatrix, Inc., H2 2012
- MSM Protein Technologies, Inc., H2 2012
- Reata Pharmaceuticals, Inc., H2 2012
- AIM Therapeutics Inc., H2 2012
- BioMarck Pharmaceuticals, Ltd., H2 2012
- Vantia Therapeutics, H2 2012
- Inverseon, Inc., H2 2012
- Polyphor Ltd., H2 2012
- NanoBio Corporation, H2 2012
- Sparsha Pharma International Pvt. Ltd., H2 2012
- iNova Pharmaceuticals (Australia) Pty Limited, H2 2012
- Adamis Pharmaceuticals Corporation, H2 2012
- SuppreMol GmbH, H2 2012
- Stelic Institute & Co., H2 2012
- Pierre Fabre Medicament, H2 2012
- Aphoenix, Inc., H2 2012
- MicroDose Therapeutx, Inc., H2 2012
- Elevation Pharmaceuticals, Inc., H2 2012
- Beech Tree Labs, Inc., H2 2012
- N30 Pharmaceuticals, H2 2012
- Errant Gene Therapeutics, LLC, H2 2012
- Stempeutics Research Private Limited, H2 2012
- Clarassance, Inc., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Drug Profile Updates
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Discontinued Products
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Discontinued Products (Contd..1)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Discontinued Products (Contd..2)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Discontinued Products (Contd..3)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Discontinued Products (Contd..4)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Discontinued Products (Contd..5)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..1)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..2)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..3)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..4)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..5)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..6)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..7)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..8)
- Chronic Obstructive Pulmonary Disease (COPD) Therapeutics – Dormant Products (Contd..9)
- List of Figures
- Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2012
- Products under Development for Chronic Obstructive Pulmonary Disease (COPD) – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractChronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2012', provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD). 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Chronic Obstructive Pulmonary Disease (COPD).
- A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Chronic Obstructive Pulmonary Disease (COPD) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
